Friday, February 25, 2011

Aplenzin


Aplenzin is a brand name of bupropion, approved by the FDA in the following formulation(s):


APLENZIN (bupropion hydrobromide - tablet, extended release; oral)



  • Manufacturer: VALEANT INTL

    Approval date: April 23, 2008

    Strength(s): 174MG, 348MG [RLD], 522MG

Has a generic version of Aplenzin been approved?


No. There is currently no therapeutically equivalent version of Aplenzin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aplenzin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Modified release formulations of a bupropion salt
    Patent 7,241,805
    Issued: July 10, 2007
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Turchetta; Stefano & Jackson; Graham & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories, Inc.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,569,610
    Issued: August 4, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International SRL
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS




  • Modified release formulations of a bupropion salt
    Patent 7,572,935
    Issued: August 11, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Turchetta; Stefano & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,585,897
    Issued: September 8, 2009
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.r.l.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Bupropion hydrobromide and therapeutic applications
    Patent 7,645,802
    Issued: January 12, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty & Jackson; Graham
    Assignee(s): Biovail Laboratories International SRL.
    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,649,019
    Issued: January 19, 2010
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Modified release formulations of a bupropion salt
    Patent 7,662,407
    Issued: February 16, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product




  • Bupropion hydrobromide and therapeutic applications
    Patent 7,671,094
    Issued: March 2, 2010
    Inventor(s): Williams; Robert Parry & Silverstone; Peter Harris
    Assignee(s): Biovail Laboratories International S.R.L.
    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product



See also...

  • Aplenzin Consumer Information (Drugs.com)
  • Aplenzin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Aplenzin Consumer Information (Cerner Multum)
  • Aplenzin Advanced Consumer Information (Micromedex)
  • Bupropion Consumer Information (Drugs.com)
  • Bupropion Consumer Information (Wolters Kluwer)
  • Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Consumer Information (Cerner Multum)
  • Bupropion Advanced Consumer Information (Micromedex)
  • Bupropion Hydrochloride AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)